Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Journal of Medicinal Chemistry [55: 4521-4525, 2012] on the anti-tumor activity of its RX-3117 compound.
The data demonstrates the synthesis of RX-3117 and its 2'-deoxy analogue, as well as its in vitro cell-line activity and strong in vivo anti-tumor effect.
"This study provides further evidence of RX-3117's potential as an anti-cancer compound," said Rick Soni, President of Rexahn. "In the preclinical study, RX-3117 significantly inhibited growth of human cancer cells in vitro and the growth of tumors in in vivo models of nude mice."
Innovative urine test could improve pancreatic cancer survival rates